Skip to main content

Search

Reset all filters
158 Result(s)
Sort by

Landmark EMPA-KIDNEY trial showed significant benefit of empagliflozin in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease

Landmark EMPA-KIDNEY trial showed significant benefit of empagliflozin in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease

EMPA-KIDNEY Phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease
More Than Scleroderma

More Than Scleroderma

A hub of knowledge, advice and support for those whose lives have been touched by scleroderma.
Nurjanahs Story

Nurjanahs Story

Nurjanah went from a sporty young woman to someone who no longer had the energy to do simple, everyday tasks. She was diagnosed with scleroderma.
Behind the Lab

Behind the Lab

Delve behind the lab to see how our Retinal Health scientists are spearheading research into novel therapeutics to treat retinopathies.
Pulmonary Fibrosis Awareness Month 2020

Pulmonary Fibrosis Awareness Month 2020

Hear what Peter Fang said about pulmonary fibrosis awareness month, our commitment to advancing care and our engaging new campaign, ‘the most important postcard you will ever write’
Cattle well-being at farms’ core

Cattle well-being at farms’ core

From pain management to responsible use of antibiotics, Cattle First introduces a whole cow approach to look after health and productivity.
Championing novel science

Championing novel science

Dr. Vikas Mohan Sharma announces FDA fast-track designation for BI 1358894 as potential treatment for Borderline Personality Disorder.
Bigger role in ensuring food security

Bigger role in ensuring food security

As the world population is projected to reach 9.8 billion in 2050, animal health becomes fundamental to ensure both animal well-being and global protein supply.